Cargando…

Barriers to physical activity in patients with pulmonary hypertension

Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) have low levels of physical activity (PA). Increased PA has health benefits including improved quality of life. This study aimed to identify patient-perceived barriers to PA that correlate w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cascino, Thomas M., McLaughlin, Vallerie V., Richardson, Caroline R., Behbahani-Nejad, Nilofar, Moles, Victor M., Visovatti, Scott H., Jackson, Elizabeth A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6540505/ https://www.ncbi.nlm.nih.gov/pubmed/30983524 http://dx.doi.org/10.1177/2045894019847895

Ejemplares similares

Impact of patient characteristics and perceived barriers on referral to exercise rehabilitation among patients with pulmonary hypertension in the United States
por: Cascino, Thomas M., et al.
Publicado: (2020)

Upfront Combination Therapy for Pulmonary Arterial Hypertension: Time to Be More Ambitious than AMBITION
por: Cascino, Thomas M., et al.
Publicado: (2021)

Increased CD39 Nucleotidase Activity on Microparticles from Patients with Idiopathic Pulmonary Arterial Hypertension
por: Visovatti, Scott H., et al.
Publicado: (2012)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Acute Right Ventricular Failure in the Setting of Acute Pulmonary Embolism or Chronic Pulmonary Hypertension: A Detailed Review of the Pathophysiology, Diagnosis, and Management
por: Matthews, Jennifer Cowger, et al.
Publicado: (2008)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis
por: Maligireddy, Anand Reddy, et al.
Publicado: (2022)

Pulmonary Hypertension: Types and Treatments
por: Rose-Jones, Lisa J, et al.
Publicado: (2015)

Risk stratification and medical therapy of pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

RACIAL DISPARITIES IN PULMONARY EMBOLISM MORTALITY AMONGST US ADULTS BEFORE AND DURING COVID-19 PANDEMIC.
por: Zghouzi, Mohamed, et al.
Publicado: (2023)

Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study
por: Visovatti, Scott H, et al.
Publicado: (2014)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
por: Rosenkranz, Stephan, et al.
Publicado: (2021)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Elevated Pulmonary Pressure Noted on Echocardiogram: A Simplified Approach to Next Steps
por: Kanwar, Manreet K., et al.
Publicado: (2021)

The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study
por: Kerr, Kim M, et al.
Publicado: (2021)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

Clinical outcomes stratified by baseline functional class after initial combination therapy for pulmonary arterial hypertension
por: White, R. James, et al.
Publicado: (2019)

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study
por: Coghlan, J Gerry, et al.
Publicado: (2014)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension
por: Humbert, Marc, et al.
Publicado: (2023)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Results From the United States Chronic Thromboembolic Pulmonary Hypertension Registry: Enrollment Characteristics and 1-Year Follow-up
por: Kerr, Kim M., et al.
Publicado: (2021)

Safety of macitentan for the treatment of pulmonary hypertension: Real‐world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

The heart of the matter: Right heart imaging indicators for treatment escalation in pulmonary arterial hypertension
por: Forfia, Paul, et al.
Publicado: (2023)

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension
por: Frantz, Robert P., et al.
Publicado: (2021)

Barriers and Facilitators to Cardiovascular Disease Prevention Following Hypertensive Disorders of Pregnancy in Primary Care: Cross-Sectional Surveys
por: Slater, Kaylee, et al.
Publicado: (2023)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
por: McLaughlin, Vallerie V., et al.
Publicado: (2017)

Overcoming the Barrier to Implementing Authentic Research Experiences through Faculty Mentorship
por: Goedhart, Christine M., et al.
Publicado: (2015)

Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension
por: Philip, Nicolas, et al.
Publicado: (2023)

Barriers and facilitators for implementing peripherally inserted central catheter (PICC) appropriateness guidelines: A longitudinal survey study from 34 Michigan hospitals
por: Ray-Barruel, Gillian, et al.
Publicado: (2022)

Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kor3fv4p7p7h2b3na06cg4ko8k